<<If the “tumor progression rate” was slowed by 46% in the Pani arm relative to the placebo arm (as was reported today), it means that PFS was lengthened by 46%, i.e. that there is 46% more area under the PFS Kaplan-Meier curve for the Pani arm than there is under the PFS Kaplan-Meier curve for the control arm.>>
Yes, PFS rate, not TTP. So, it is up to BSC PFS placebo rate number that discribe 46%? To compare (up to the points) C225 and ABX, the median (or mean) PFS is only measure (for this trial) that count. As Wilder indicated, 8 weeks for 100% BSC progression indicate median PFS value of "4 WEEKS", which is somehow short, imo. If ABX improve 46% PFS rate, their numer for median PFS is at ~6 WEEKS!
To your initial reply, it is BS to comment on trial success/failure based on "false" reading of the PR. Only numbers count, and what that numbers means in real word.
Miljenko |
